<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600988</url>
  </required_header>
  <id_info>
    <org_study_id>Alovita-1</org_study_id>
    <nct_id>NCT02600988</nct_id>
  </id_info>
  <brief_title>Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant</brief_title>
  <acronym>Alovita-1</acronym>
  <official_title>Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether vitamin D is effective in the prevention of
      graft-versus-host-disease after completion of allogeneic transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The allogeneic transplant of haematopoietic cell is the only treatment option for many
      malignant blood diseases. Unfortunately, the progression free survival and the quality of
      life of transplanted patients is limited due to the development of graft-versus-host-disease
      (GVHD).

      The development of new prophylaxis strategies of GVHD based in the use of immunomodulator
      agents (allowing the generation of an immunotolerance state and avoiding the use of
      immunosuppression) is essential.

      The GVHD is due to the cytotoxic effect of the donor lymphocytes T against healthy organs and
      tissues of the receptor. Calcineurin inhibitor combined with methotrexate or antibodies
      anti-lymphocytes T are used as standard prophylaxis. This type of antibodies has demonstrated
      efficacy to reduce GVHD, but have not increased survival due to increasing the risk of
      relapses and serious post-transplant infections.

      Due to its interactions with VDR (vitamin D receptor) present in immune system cells, vitamin
      D is able to inhibit the activation of dendritic cells and the proliferation and production
      of cytokines by lymphocytes T. Based on this effect, the peri- and post- transplant
      administration of vitamin D might decrease the risk of GVHD in allogeneic transplanted
      patients, subsequently decreasing the immunosuppressant treatment requirements and improving
      the prognosis of those patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence/severity of Graft-Versus-Host-Disease</measure>
    <time_frame>Day +150 post-transplant</time_frame>
    <description>Number of cases of GVHD/Seriousness graded according to National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Th1/Th2 cytokines</measure>
    <time_frame>Day -5 pre-transplant and +1, +7, +21,+56 and +100 post-transplant</time_frame>
    <description>(IL-2, IL-4, IL-6, IL-10, tumor necrosis factor alfa (TNF)-α and interferon gamma (IFN-g)) are determined by flow cytometry using the BD Human Th1/Th2 Cytokine CBA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dendritic cells</measure>
    <time_frame>Day +21,+56 and +100 post-transplant</time_frame>
    <description>The following markers were used to identify different subpopulations
CD16-PB, CD45-V500, HLADR-FITC, BDCA-PE, CD11c-PerCP-Cy5.5, CD86-PE-Cy7, CD123-APC and CD14-APC-H7.
Plasmacytoid dendritic cells: HLADR+ CD123++ CD11c- CD16- CD14- BDCA1- CD45+.
Monocyte-derived dendritic cells: HLADR+ CD123+d CD11c+ CD16++ CD14-/+d BDCA- CD45+.
Myeloid BDCA1 dendritic cells : HLADR+ CD123- CD11c+ CD16- CD14- BDCA+ CD45+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subpopulations of lymphocytes</measure>
    <time_frame>Day +21,+56 and +100 post-transplant</time_frame>
    <description>To be identified using the combination CD19+CD8-FITC, CD3+CD56-PE, CD4- PerCP-Cy5.5, HLADR-APC T cells: CD3+ (CD3+CD4+CD8-, CD3+CD4-CD8+, CD3+CD4+CD8+, CD3+CD4-CD8+)
B cells: CD19+ HLADR+
NK cells: CD3- CD19- CD56+
CD45RA-FITC and CCR7-PE were used to distinguish the repertory of naive/effector/memory of CD4 and CD8 cells.
-naive T cells: CD45RA+CCR7+
-effector T cells: CD45RA+CCR7-
-central memory T cells: CD45RA-CCR7+
-Peripheral memory T cells: CD45RA-CCR7-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regulatory T cells</measure>
    <time_frame>Day +21,+56 and +100 post-transplant</time_frame>
    <description>after incubation of surface antigens (CD25-FITC, CD127-PE and CD4-PerCP-Cy5.5), cells were washed in PBS and then fixed and permeabilized with FoxP3 Staining Buffer Set (eBiosciences) for FOXP3 staining.
phenotype of Treg: CD4+CD25+CD127-/+wFoxP3+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK markers</measure>
    <time_frame>Day +21,+56 and +100 post-transplant</time_frame>
    <description>using the following combinations:
CD94-FITC/CD56-PE/CD3-PerCP-Cy5.5/HLADR-APC
CD11a-FITC/CD16-PE/CD3-PerCP-Cy5.5/CD56-APC
CD158a-FITC/CD161-PE/CD3-PerCP-Cy5.5/CD56-APC
CDNKB1-FITC/NKAT-PE/CD3-PerCP-Cy5.5/CD56-APC
We identify NK cells with weak expression of CD56 (CD56 called &quot; weak) and those expressing more intensely this marker CD56 &quot;bright &quot;. In addition the expression of different KIR receptor as CD158a , CD161 , and NKAT2 NKB1 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of T cells</measure>
    <time_frame>Day +21,+56 and +100 post-transplant</time_frame>
    <description>Activation assays are performed on 500 µl of peripheral blood added in 48-well plates. Peripheral blood is stimulated or not with PMA (20µg/2ml) and ionomycin (0.91 µg/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Vitamin D</measure>
    <time_frame>Day -5 pre-transplant and +1, +7 and +21 post-transplant</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration of Vitamin D</measure>
    <time_frame>Day -5 pre-transplant and +1, +7 and +21 post-transplant</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone densitometry changes carried out by protocol in post-transplant period</measure>
    <time_frame>Day +150 post-transplant</time_frame>
    <description>Treatment effect in the subsequent development of osteoporosis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Group 1: Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 1000IU/day of Vitamine D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 5000IU/day of Vitamine D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000IU/day of Vitamine D</intervention_name>
    <description>Administration of a specified dose of Vitamine D</description>
    <arm_group_label>Group 2: 1000IU/day of Vitamine D</arm_group_label>
    <other_name>Vitamine D dose of 1000 international units (IU)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5000IU/day of Vitamine D</intervention_name>
    <description>Administration of a specified dose of Vitamine D</description>
    <arm_group_label>Group 3: 5000IU/day of Vitamine D</arm_group_label>
    <other_name>Vitamine D dose of 5000 international units (IU)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  The patient should accomplish all the criteria to proceed to an allogeneic transplant

          -  The patient or their legal guardians should signed the informed consent approved by
             the Ethics Committees of Clinical Trials

        Exclusion Criteria:

          -  Hypercalcemia ≥ 10.5 mg/dl

          -  Renal insufficiency with creatinine level ≥ 2 x upper limit of normal (1,1 mg/dl)

          -  Participation in others Clinical Trials in which the intervention may affect the
             result of the study.

          -  Patients receiving GVHD immunoprophylaxis with thymoglobuline or GVHD prophylaxis
             including in vitro or in vivo lymphocytes T depletion (anti-lymphocyte T globulin,
             ALG)

          -  Patients receiving a transplant from an haploidentical donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Antonio Pérez-Simón, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of haematology department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christelle Ferrà i Coll</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raquel Saldaña Moreno</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmen Martínez</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Valcárcel Ferreiras</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manuel Jurado Chacón</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mª Ángeles Cuesta</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fermín Martín Sánchez- Guijo</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft-Versus-Host-Disease</keyword>
  <keyword>post-allogeneic transplant</keyword>
  <keyword>haematopoietic progenitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

